| Year |
Citation |
Score |
| 2023 |
Serwetnyk MA, Crowley VM, Brackett CM, Carter TR, Elahi A, Kommalapati VK, Chadli A, Blagg BSJ. Enniatin A Analogues as Novel Hsp90 Inhibitors that Modulate Triple-Negative Breast Cancer. Acs Medicinal Chemistry Letters. 14: 1785-1790. PMID 38116437 DOI: 10.1021/acsmedchemlett.3c00423 |
0.482 |
|
| 2023 |
Pal R, Hui D, Menchen H, Zhao H, Mozziconacci O, Wilkins H, Blagg BSJ, Schöneich C, Swerdlow RH, Michaelis ML, Michaelis EK. Protection against Aβ-induced neuronal damage by KU-32: PDHK1 inhibition as important target. Frontiers in Aging Neuroscience. 15: 1282855. PMID 38035268 DOI: 10.3389/fnagi.2023.1282855 |
0.314 |
|
| 2023 |
Eisa NH, Crowley VM, Elahi A, Kommalapati VK, Serwetnyk MA, Llbiyi T, Lu S, Kainth K, Jilani Y, Marasco D, El Andaloussi A, Lee S, Tsai FTF, Rodriguez PC, Munn D, ... ... Blagg B, et al. Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer. Iscience. 26: 108308. PMID 38025772 DOI: 10.1016/j.isci.2023.108308 |
0.348 |
|
| 2023 |
Reynolds TS, Blagg BSJ. Synthesis and Validation of the First Cell-Impermeable Hsp90α-Selective Inhibitors. Acs Medicinal Chemistry Letters. 14: 1250-1256. PMID 37736193 DOI: 10.1021/acsmedchemlett.3c00265 |
0.415 |
|
| 2023 |
Merfeld T, Peng S, Keegan BM, Crowley VM, Brackett CM, Gutierrez A, McCann NR, Reynolds TS, Rhodes MC, Byrd KM, Deng J, Matts RL, Blagg BSJ. Elucidation of novel TRAP1-Selective inhibitors that regulate mitochondrial processes. European Journal of Medicinal Chemistry. 258: 115531. PMID 37307624 DOI: 10.1016/j.ejmech.2023.115531 |
0.643 |
|
| 2023 |
Dou X, Guo H, D'Amico T, Abdallah L, Subramanian C, Patel BA, Cohen M, Rubinstein JL, Blagg B. CryoEM Structure with ATP Synthase Enables Late-stage Diversification of Cruentaren A. Chemistry (Weinheim An Der Bergstrasse, Germany). e202300262. PMID 36867738 DOI: 10.1002/chem.202300262 |
0.336 |
|
| 2022 |
Amatya E, Blagg BSJ. Recent advances toward the development of Hsp90 C-terminal inhibitors. Bioorganic & Medicinal Chemistry Letters. 80: 129111. PMID 36549397 DOI: 10.1016/j.bmcl.2022.129111 |
0.413 |
|
| 2022 |
Mishra SJ, Reynolds TS, Merfeld T, Balch M, Peng S, Deng J, Matts R, Blagg BSJ. Structure-Activity Relationship Study of Tertiary Alcohol Hsp90α-Selective Inhibitors with Novel Binding Mode. Acs Medicinal Chemistry Letters. 13: 1870-1878. PMID 36518703 DOI: 10.1021/acsmedchemlett.2c00327 |
0.377 |
|
| 2022 |
Keegan BM, Blagg BSJ. A Split Luciferase Complementation Assay for the Evaluation of Hsp90/Aha1 Complex Disruptors and Their Activity at the Aha1 C-Terminal Domain. Acs Chemical Biology. 18: 184-192. PMID 36516069 DOI: 10.1021/acschembio.2c00854 |
0.376 |
|
| 2022 |
Rahmy S, Mishra SJ, Murphy S, Blagg BSJ, Lu X. Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors. Frontiers in Immunology. 13: 1005045. PMID 36341371 DOI: 10.3389/fimmu.2022.1005045 |
0.358 |
|
| 2022 |
Meka PN, Amatya E, Kaur S, Banerjee M, Zuo A, Dobrowsky RT, Blagg BSJ. Synthesis and evaluation of 3'- and 4'-substituted cyclohexyl noviomimetics that modulate mitochondrial respiration. Bioorganic & Medicinal Chemistry. 70: 116940. PMID 35905686 DOI: 10.1016/j.bmc.2022.116940 |
0.629 |
|
| 2022 |
Dou X, Patel BA, D'Amico T, Subramanian C, Cousineau E, Yi Y, Cohen M, Blagg BSJ. Synthesis and Evaluation of Simplified Cruentaren A Analogues. The Journal of Organic Chemistry. PMID 35894845 DOI: 10.1021/acs.joc.2c00948 |
0.465 |
|
| 2022 |
Keegan BM, Catalfano KC, Banerjee M, Blagg BSJ. Synthesis and Evaluation of Small Molecule Disruptors of the Aha1/Hsp90 Complex for the Reduction of Tau Aggregation. Acs Medicinal Chemistry Letters. 13: 827-832. PMID 35586436 DOI: 10.1021/acsmedchemlett.2c00064 |
0.384 |
|
| 2021 |
Patil VM, Masand N, Gupta SP, Blagg BSJ. QSAR Studies to Predict Activity of HSP90 Inhibitors. Current Topics in Medicinal Chemistry. 21: 2272-2291. PMID 34635040 DOI: 10.2174/1568026621666211011095858 |
0.395 |
|
| 2021 |
Kurop MK, Huyen CM, Kelly JH, Blagg BSJ. The heat shock response and small molecule regulators. European Journal of Medicinal Chemistry. 226: 113846. PMID 34563965 DOI: 10.1016/j.ejmech.2021.113846 |
0.339 |
|
| 2021 |
Pipalia NH, Saad SZ, Subramanian K, Cross A, Al-Motawa A, Garg K, Blagg BSJ, Neckers L, Helquist P, Wiest O, Ory DS, Maxfield FR. HSP90 inhibitors reduce cholesterol storage in Niemann-Pick type C1 mutant fibroblasts. Journal of Lipid Research. 100114. PMID 34481829 DOI: 10.1016/j.jlr.2021.100114 |
0.57 |
|
| 2021 |
Blagg B, Chaudhury S, Meka PN, Banerjee M, Kent CN. Structure-based design, synthesis, and biological evaluation of Hsp90β-selective inhibitors. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 34449940 DOI: 10.1002/chem.202102574 |
0.466 |
|
| 2021 |
Serwetnyk MA, Blagg BSJ. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharmaceutica Sinica. B. 11: 1446-1468. PMID 34221862 DOI: 10.1016/j.apsb.2020.11.015 |
0.472 |
|
| 2021 |
Serwetnyk MA, Blagg BSJ. The disruption of protein-protein interactions with co-chaperones and client substrates as a strategy towards Hsp90 inhibition. Acta Pharmaceutica Sinica. B. 11: 1446-1468. PMID 34221862 DOI: 10.1016/j.apsb.2020.11.015 |
0.472 |
|
| 2021 |
Sanchez JN, Subramanian C, Chanda M, Shanguan G, Zhang N, Wang T, Timmermann BN, Blagg BSJ, Cohen MS. A novel C-terminal Hsp90 inhibitor KU758 synergizes efficacy in combination with BRAF or MEK inhibitors and targets drug-resistant pathways in BRAF-mutant melanomas. Melanoma Research. 31: 197-207. PMID 33904516 DOI: 10.1097/CMR.0000000000000734 |
0.338 |
|
| 2021 |
Tosh DK, Brackett CM, Jung YH, Gao ZG, Banerjee M, Blagg BSJ, Jacobson KA. Biological Evaluation of 5'-(-Ethylcarboxamido)adenosine Analogues as Grp94-Selective Inhibitors. Acs Medicinal Chemistry Letters. 12: 373-379. PMID 33738064 DOI: 10.1021/acsmedchemlett.0c00509 |
0.369 |
|
| 2021 |
Blagg B, Mishra S, Khandelwal A, Bannerjee M, Balch M, Peng S, Davis R, Merfeld T, Menthali V, Deng J, Matts R. Selective Inhibition of the Hsp90a isoform. Angewandte Chemie (International Ed. in English). PMID 33621416 DOI: 10.1002/anie.202015422 |
0.456 |
|
| 2021 |
Mishra SJ, Liu W, Beebe K, Banerjee M, Kent CN, Munthali V, Koren J, Taylor JA, Neckers LM, Holzbeierlein J, Blagg BSJ. The Development of Hsp90β-Selective Inhibitors to Overcome Detriments Associated with -Hsp90 Inhibition. Journal of Medicinal Chemistry. PMID 33428418 DOI: 10.1021/acs.jmedchem.0c01700 |
0.457 |
|
| 2020 |
Banerjee M, Hatial I, Keegan BM, Blagg BSJ. Assay design and development strategies for finding Hsp90 inhibitors and their role in human diseases. Pharmacology & Therapeutics. 107747. PMID 33245994 DOI: 10.1016/j.pharmthera.2020.107747 |
0.419 |
|
| 2020 |
Tomašič T, Durcik M, Keegan BM, Skledar DG, Zajec Ž, Blagg BSJ, Bryant SD. Discovery of Novel Hsp90 C-Terminal Inhibitors Using 3D-Pharmacophores Derived from Molecular Dynamics Simulations. International Journal of Molecular Sciences. 21. PMID 32962253 DOI: 10.3390/ijms21186898 |
0.455 |
|
| 2020 |
Chaudhury S, Keegan BM, Blagg BSJ. The role and therapeutic potential of Hsp90, Hsp70, and smaller heat shock proteins in peripheral and central neuropathies. Medicinal Research Reviews. PMID 32844464 DOI: 10.1002/med.21729 |
0.369 |
|
| 2020 |
Pugh KW, Zhang Z, Wang J, Xu X, Munthali V, Zuo A, Blagg BSJ. From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition. Acs Medicinal Chemistry Letters. 11: 1535-1538. PMID 32832020 DOI: 10.1021/Acsmedchemlett.0C00100 |
0.716 |
|
| 2020 |
Subramanian C, Gorney R, Wang T, Ge D, Zhang N, Zuo A, Blagg BSJ, Cohen MS. A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro. Surgery. PMID 32718802 DOI: 10.1016/J.Surg.2020.06.009 |
0.637 |
|
| 2020 |
Birar VC, Gelis I, Zuo A, Blagg BSJ. Synthesis of paramagnetic ligands that target the C-terminal binding site of Hsp90. Bioorganic & Medicinal Chemistry Letters. 30: 127303. PMID 32631523 DOI: 10.1016/J.Bmcl.2020.127303 |
0.631 |
|
| 2020 |
Stine C, Coleman DL, Flohrschutz AT, Thompson AL, Mishra S, Blagg BS, Largent-Milnes TM, Lei W, Streicher JM. Heat shock protein 90 inhibitors block the anti-nociceptive effects of opioids in mouse chemotherapy-induced neuropathy and cancer bone pain models. Pain. PMID 32301839 DOI: 10.1097/j.pain.0000000000001886 |
0.306 |
|
| 2020 |
Koren J, Blagg BSJ. The Right Tool for the Job: An Overview of Hsp90 Inhibitors. Advances in Experimental Medicine and Biology. 1243: 135-146. PMID 32297216 DOI: 10.1007/978-3-030-40204-4_9 |
0.414 |
|
| 2020 |
Subramanian C, Grogan PT, Wang T, Bazzill J, Zuo A, White PT, Kalidindi A, Kuszynski D, Wang G, Blagg BSJ, Cohen MS. Novel C-terminal heat shock protein 90 inhibitors target breast cancer stem cells and block migration, self-renewal, and epithelial-mesenchymal transition. Molecular Oncology. PMID 32255264 DOI: 10.1002/1878-0261.12686 |
0.664 |
|
| 2019 |
Kaur J, Bhardwaj A, Melancon BJ, Blagg BSJ. The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor. Synthetic Communications. 49: 1436-1443. PMID 33093687 DOI: 10.1080/00397911.2019.1602654 |
0.353 |
|
| 2019 |
Sanchez J, Carter TR, Cohen MS, Blagg BS. Old and New Approaches to Target the Hsp90 Chaperone. Current Cancer Drug Targets. PMID 31793427 DOI: 10.2174/1568009619666191202101330 |
0.425 |
|
| 2019 |
Zhang Z, Banerjee M, Davis RE, Blagg BSJ. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity. Bioorganic & Medicinal Chemistry Letters. 126676. PMID 31591016 DOI: 10.1016/j.bmcl.2019.126676 |
0.41 |
|
| 2019 |
Chatterjee BK, Jayaraj A, Kumar V, Blagg B, Davis RE, Jayaram B, Deep S, Chaudhuri TK. Stimulation of heat shock protein 90 chaperone function through binding of a novobiocin analog KU-32. The Journal of Biological Chemistry. PMID 30792306 DOI: 10.1074/Jbc.Ra118.002502 |
0.538 |
|
| 2018 |
Kumar Mv V, Ebna Noor R, Davis RE, Zhang Z, Sipavicius E, Keramisanou D, Blagg BSJ, Gelis I. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain. Medchemcomm. 9: 1323-1331. PMID 30151087 DOI: 10.1039/c8md00151k |
0.37 |
|
| 2018 |
Zhang Z, You Z, Dobrowsky RT, Blagg BSJ. Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity. Bioorganic & Medicinal Chemistry Letters. PMID 29759728 DOI: 10.1016/J.Bmcl.2018.03.071 |
0.448 |
|
| 2018 |
Forsberg LK, Davis RE, Wimalasena VK, Blagg BSJ. Exploiting polarity and chirality to probe the Hsp90 C-terminus. Bioorganic & Medicinal Chemistry. PMID 29720349 DOI: 10.1016/j.bmc.2018.04.028 |
0.372 |
|
| 2018 |
Sheehan A, Messer AE, Papadaki M, Choudhry A, Kren V, Biedermann D, Blagg B, Khandelwal A, Marston SB. Molecular Defects in Cardiac Myofilament Ca-Regulation Due to Cardiomyopathy-Linked Mutations Can Be Reversed by Small Molecules Binding to Troponin. Frontiers in Physiology. 9: 243. PMID 29636697 DOI: 10.3389/fphys.2018.00243 |
0.322 |
|
| 2018 |
Que NLS, Crowley VM, Duerfeldt AS, Zhao J, Kent CN, Blagg BSJ, Gewirth DT. Structure based design of a Grp94-selective inhibitor: Exploiting a key residue in Grp94 to optimize paralog-selective binding. Journal of Medicinal Chemistry. PMID 29528635 DOI: 10.1021/Acs.Jmedchem.7B01608 |
0.805 |
|
| 2018 |
Byrd KM, Blagg BSJ. Chaperone substrate provides missing link for cancer drug discovery. The Journal of Biological Chemistry. 293: 2381-2382. PMID 29453286 DOI: 10.1074/jbc.H118.001591 |
0.672 |
|
| 2018 |
Huard DJ, Crowley VM, Du Y, Cordova RA, Sun Z, Tomlin MO, Dickey CA, Koren J, Blair L, Fu H, Blagg BSJ, Lieberman RL. Trifunctional high-throughput screen identifies promising scaffold to inhibit Grp94 and treat myocilin-associated glaucoma. Acs Chemical Biology. PMID 29402077 DOI: 10.1021/Acschembio.7B01083 |
0.371 |
|
| 2018 |
Neckers L, Blagg B, Haystead T, Trepel JB, Whitesell L, Picard D. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. Cell Stress & Chaperones. PMID 29392504 DOI: 10.1007/S12192-018-0877-2 |
0.373 |
|
| 2018 |
Khandelwal A, Kent CN, Balch M, Peng S, Mishra SJ, Deng J, Day VW, Liu W, Subramanian C, Cohen M, Holzbeierlein JM, Matts R, Blagg BSJ. Structure-guided design of an Hsp90β N-terminal isoform-selective inhibitor. Nature Communications. 9: 425. PMID 29382832 DOI: 10.1038/S41467-017-02013-1 |
0.467 |
|
| 2017 |
Stothert AR, Suntharalingam A, Tang X, Crowley VM, Mishra SJ, Webster JM, Nordhues BA, Huard DJE, Passaglia CL, Lieberman RL, Blagg BSJ, Blair LJ, Koren J, Dickey CA. Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma. Scientific Reports. 7: 17951. PMID 29263415 DOI: 10.1038/S41598-017-18344-4 |
0.397 |
|
| 2017 |
Forsberg LK, Anyika M, You Z, Emery S, McMullen M, Dobrowsky RT, Blagg BSJ. Development of noviomimetics that modulate molecular chaperones and manifest neuroprotective effects. European Journal of Medicinal Chemistry. PMID 29137866 DOI: 10.1016/J.Ejmech.2017.10.038 |
0.438 |
|
| 2017 |
Byrd K, Kent C, Blagg B. Synthesis and biological evaluation of stilbene analogs as Hsp90 C-terminal inhibitors. Chemmedchem. PMID 29058824 DOI: 10.1002/cmdc.201700630 |
0.651 |
|
| 2017 |
Khandelwal A, Crowley VM, Blagg BSJ. Resorcinol-Based Grp94-Selective Inhibitors. Acs Medicinal Chemistry Letters. 8: 1013-1018. PMID 29057043 DOI: 10.1021/acsmedchemlett.7b00193 |
0.343 |
|
| 2017 |
Forsberg L, Garg G, Zhao H, Blagg B. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 C-terminal Inhibitors. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28940589 DOI: 10.1002/chem.201703206 |
0.464 |
|
| 2017 |
Crowley V, Huard D, Lieberman R, Blagg B. Second Generation Grp94-selective Inhibitors Provide Opportunities for the Inhibition of Metastatic Cancer. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28857290 DOI: 10.1002/Chem.201703398 |
0.423 |
|
| 2017 |
Forsberg LK, Liu W, Holzbeierlein J, Blagg BSJ. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer. Bioorganic & Medicinal Chemistry Letters. PMID 28844386 DOI: 10.1016/j.bmcl.2017.07.030 |
0.443 |
|
| 2017 |
Davis RE, Zhang Z, Blagg BSJ. A Scaffold Merging Approach to Hsp90 C-terminal Inhibition: Synthesis and Evaluation of a Chimeric Library. Medchemcomm. 8: 593-598. PMID 28533894 DOI: 10.1039/C6MD00377J |
0.432 |
|
| 2017 |
Byrd KM, Kent CN, Blagg BSJ. Cover Feature: Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 C-Terminal Inhibitors (ChemMedChem 24/2017) Chemmedchem. 12: 2015-2015. DOI: 10.1002/cmdc.201700751 |
0.347 |
|
| 2016 |
Mishra SJ, Ghosh S, Stothert AR, Dickey CA, Blagg BS. Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold. Acs Chemical Biology. PMID 27959508 DOI: 10.1021/Acschembio.6B00747 |
0.435 |
|
| 2016 |
Garg G, Zhao H, Blagg BS. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors. Bioorganic & Medicinal Chemistry. PMID 27914946 DOI: 10.1016/J.Bmc.2016.11.030 |
0.428 |
|
| 2016 |
Ghosh S, Liu Y, Garg G, Anyika M, McPherson NT, Ma J, Dobrowsky RT, Blagg BS. Diverging Novobiocin Anti-Cancer Activity from Neuroprotective Activity through Modification of the Amide Tail. Acs Medicinal Chemistry Letters. 7: 813-8. PMID 27563408 DOI: 10.1021/Acsmedchemlett.6B00224 |
0.371 |
|
| 2016 |
Byrd KM, Subramanian C, Sanchez J, Motiwala HF, Liu W, Cohen MS, Holzbeierlein J, Blagg BS. Synthesis and Biological Evaluation of Novobiocin Core Analogues as Hsp90 Inhibitors. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 27037933 DOI: 10.1002/chem.201504955 |
0.684 |
|
| 2016 |
Crowley VM, Khandelwal A, Mishra S, Stothert AR, Huard DJ, Zhao J, Muth A, Duerfeldt AS, Kizziah JL, Lieberman RL, Dickey CA, Blagg BS. Development of Glucose Regulated Protein 94-Selective Inhibitors based on the BnIm and Radamide Scaffold. Journal of Medicinal Chemistry. PMID 27003516 DOI: 10.1021/Acs.Jmedchem.6B00085 |
0.832 |
|
| 2016 |
Di XJ, Wang YJ, Han DY, Fu YL, Duerfeldt AS, Blagg BS, Mu TW. Grp94 Delivers γ-aminobutyric Acid Type A (GABAA) Receptors to Hrd1-Mediatd Endoplasmic Reticulum-Associated Degradation. The Journal of Biological Chemistry. PMID 26945068 DOI: 10.1074/Jbc.M115.705004 |
0.766 |
|
| 2016 |
Garg G, Khandelwal A, Blagg BS. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects. Advances in Cancer Research. 129: 51-88. PMID 26916001 DOI: 10.1016/bs.acr.2015.12.001 |
0.477 |
|
| 2016 |
Ghosh S, Shinogle HE, Galeva NA, Dobrowsky RT, Blagg BS. Endoplasmic Reticulum Resident Heat Shock Protein 90 (Hsp90) Isoform Glucose-Regulated Protein 94 (Grp94) Regulates Cell Polarity and Cancer Cell Migration by Affecting Intracellular Transport. The Journal of Biological Chemistry. PMID 26872972 DOI: 10.1074/Jbc.M115.688374 |
0.327 |
|
| 2016 |
Anyika M, McMullen M, Forsberg LK, Dobrowsky RT, Blagg BS. Development of Noviomimetics as C-Terminal Hsp90 Inhibitors. Acs Medicinal Chemistry Letters. 7: 67-71. PMID 26819668 DOI: 10.1021/Acsmedchemlett.5B00331 |
0.45 |
|
| 2016 |
Hall J, Seedarala S, Zhao H, Garg G, Ghosh S, Blagg BS. Novobiocin Analogs That Inhibit the MAPK Pathway. Journal of Medicinal Chemistry. PMID 26745854 DOI: 10.1021/Acs.Jmedchem.5B01354 |
0.453 |
|
| 2015 |
Dunn DM, Woodford MR, Truman AW, Jensen SM, Schulman J, Caza T, Remillard TC, Loiselle D, Wolfgeher D, Blagg BS, Franco L, Haystead TA, Daturpalli S, Mayer MP, Trepel JB, et al. c-Abl Mediated Tyrosine Phosphorylation of Aha1 Activates Its Co-chaperone Function in Cancer Cells. Cell Reports. 12: 1006-18. PMID 26235616 DOI: 10.1016/J.Celrep.2015.07.004 |
0.406 |
|
| 2015 |
Khandelwal A, Crowley VM, Blagg BS. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside? Medicinal Research Reviews. PMID 26010985 DOI: 10.1002/med.21351 |
0.444 |
|
| 2015 |
Liu W, Vielhauer GA, Holzbeierlein JM, Zhao H, Ghosh S, Brown D, Lee E, Blagg BS. KU675, a Concomitant Heat-Shock Protein Inhibitor of Hsp90 and Hsc70 that Manifests Isoform Selectivity for Hsp90α in Prostate Cancer Cells. Molecular Pharmacology. 88: 121-30. PMID 25939977 DOI: 10.1124/Mol.114.097303 |
0.431 |
|
| 2015 |
Hall JA, Seedarala S, Rice N, Kopel L, Halaweish F, Blagg BS. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery. Journal of Natural Products. 78: 873-9. PMID 25756299 DOI: 10.1021/Acs.Jnatprod.5B00054 |
0.408 |
|
| 2015 |
Garg G, Zhao H, Blagg BS. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as hsp90 C-terminal inhibitors. Acs Medicinal Chemistry Letters. 6: 204-9. PMID 25699150 DOI: 10.1021/Ml5004475 |
0.47 |
|
| 2015 |
Zhao H, Garg G, Zhao J, Moroni E, Girgis A, Franco LS, Singh S, Colombo G, Blagg BS. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors. European Journal of Medicinal Chemistry. 89: 442-66. PMID 25462258 DOI: 10.1016/J.Ejmech.2014.10.034 |
0.459 |
|
| 2015 |
Ghosh S, Shinogle HE, Garg G, Vielhauer GA, Holzbeierlein JM, Dobrowsky RT, Blagg BS. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90α/Aha1 complex in PC3-MM2 cells. Acs Chemical Biology. 10: 577-90. PMID 25402753 DOI: 10.1021/Cb5008713 |
0.397 |
|
| 2014 |
Hall JA, Forsberg LK, Blagg BS. Alternative approaches to Hsp90 modulation for the treatment of cancer. Future Medicinal Chemistry. 6: 1587-605. PMID 25367392 DOI: 10.4155/fmc.14.89 |
0.463 |
|
| 2014 |
Zhao J, Zhao H, Hall JA, Brown D, Brandes E, Bazzill J, Grogan PT, Subramanian C, Vielhauer G, Cohen MS, Blagg BS. Triazole Containing Novobiocin and Biphenyl Amides as Hsp90 C-Terminal Inhibitors. Medchemcomm. 5: 1317-1323. PMID 25328661 DOI: 10.1039/C4Md00102H |
0.469 |
|
| 2014 |
Muth A, Crowley V, Khandelwal A, Mishra S, Zhao J, Hall J, Blagg BS. Development of radamide analogs as Grp94 inhibitors. Bioorganic & Medicinal Chemistry. 22: 4083-98. PMID 25027801 DOI: 10.1016/J.Bmc.2014.05.075 |
0.392 |
|
| 2014 |
Zhao H, Anyika M, Girgis A, Blagg BS. Novologues containing a benzamide side chain manifest anti-proliferative activity against two breast cancer cell lines. Bioorganic & Medicinal Chemistry Letters. 24: 3633-7. PMID 24953820 DOI: 10.1016/J.Bmcl.2014.05.020 |
0.356 |
|
| 2014 |
Zhao H, Moroni E, Colombo G, Blagg BS. Identification of a new scaffold for hsp90 C-terminal inhibition. Acs Medicinal Chemistry Letters. 5: 84-8. PMID 24900777 DOI: 10.1021/Ml400404S |
0.446 |
|
| 2014 |
Davenport J, Balch M, Galam L, Girgis A, Hall J, Blagg BS, Matts RL. High-throughput screen of natural product libraries for hsp90 inhibitors. Biology. 3: 101-38. PMID 24833337 DOI: 10.3390/Biology3010101 |
0.433 |
|
| 2014 |
Kusuma BR, Khandelwal A, Gu W, Brown D, Liu W, Vielhauer G, Holzbeierlein J, Blagg BS. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry. 22: 1441-9. PMID 24461493 DOI: 10.1016/j.bmc.2013.12.056 |
0.421 |
|
| 2014 |
Hall JA, Kusuma BR, Brandt GE, Blagg BS. Cruentaren A binds F1F0 ATP synthase to modulate the Hsp90 protein folding machinery. Acs Chemical Biology. 9: 976-85. PMID 24450340 DOI: 10.1021/cb400906e |
0.81 |
|
| 2014 |
Patwardhan CA, Peterson LB, Blagg B, Chadli A. Abstract 3197: Gedunin inactivates the co-chaperone p23 causing cancer cell death by apoptosis Cancer Research. 74: 3197-3197. DOI: 10.1158/1538-7445.Am2014-3197 |
0.688 |
|
| 2013 |
Sadikot T, Swink M, Eskew JD, Brown D, Zhao H, Kusuma BR, Rajewski RA, Blagg BS, Matts RL, Holzbeierlein JM, Vielhauer GA. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. Assay and Drug Development Technologies. 11: 478-88. PMID 24127661 DOI: 10.1089/Adt.2012.498 |
0.44 |
|
| 2013 |
Khandelwal A, Hall JA, Blagg BS. Synthesis and structure-activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor. The Journal of Organic Chemistry. 78: 7859-84. PMID 23834230 DOI: 10.1021/jo401027r |
0.465 |
|
| 2013 |
Patwardhan CA, Fauq A, Peterson LB, Miller C, Blagg BS, Chadli A. Gedunin inactivates the co-chaperone p23 protein causing cancer cell death by apoptosis. The Journal of Biological Chemistry. 288: 7313-25. PMID 23355466 DOI: 10.1074/Jbc.M112.427328 |
0.667 |
|
| 2013 |
Zhao H, Blagg BS. Novobiocin analogues with second-generation noviose surrogates. Bioorganic & Medicinal Chemistry Letters. 23: 552-7. PMID 23234644 DOI: 10.1016/J.Bmcl.2012.11.022 |
0.453 |
|
| 2013 |
Zeineldin M, McGuinness W, Blagg B, Rajewski R, Neufeld KL. Abstract 2728: Induction of the heat-shock response upregulates the tumor suppressor APC and alters intestinal tumorigenesis in mice. Cancer Research. 73: 2728-2728. DOI: 10.1158/1538-7445.Am2013-2728 |
0.336 |
|
| 2012 |
Zhao H, Moroni E, Yan B, Colombo G, Blagg BS. 3D-QSAR Assisted Design, Synthesis and Evaluation of Novobiocin Analogues. Acs Medicinal Chemistry Letters. 4: 57-62. PMID 23606927 DOI: 10.1021/Ml300275G |
0.411 |
|
| 2012 |
Zhao H, Yan B, Peterson LB, Blagg BS. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition. Acs Medicinal Chemistry Letters. 3: 327-331. PMID 23316269 DOI: 10.1021/Ml300018E |
0.709 |
|
| 2012 |
Kusuma BR, Brandt GE, Blagg BS. Synthesis of cruentaren A. Organic Letters. 14: 6242-5. PMID 23205851 DOI: 10.1021/ol302999v |
0.794 |
|
| 2012 |
Suntharalingam A, Abisambra JF, O'Leary JC, Koren J, Zhang B, Joe MK, Blair LJ, Hill SE, Jinwal UK, Cockman M, Duerfeldt AS, Tomarev S, Blagg BS, Lieberman RL, Dickey CA. Glucose-regulated protein 94 triage of mutant myocilin through endoplasmic reticulum-associated degradation subverts a more efficient autophagic clearance mechanism. The Journal of Biological Chemistry. 287: 40661-9. PMID 23035116 DOI: 10.1074/Jbc.M112.384800 |
0.796 |
|
| 2012 |
Iwai A, Bourboulia D, Mollapour M, Jensen-Taubman S, Lee S, Donnelly AC, Yoshida S, Miyajima N, Tsutsumi S, Smith AK, Sun D, Wu X, Blagg BS, Trepel JB, Stetler-Stevenson WG, et al. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells. Cell Cycle (Georgetown, Tex.). 11: 3649-55. PMID 22935698 DOI: 10.4161/Cc.21926 |
0.784 |
|
| 2012 |
Zhao H, Michaelis ML, Blagg BS. Hsp90 modulation for the treatment of Alzheimer's disease. Advances in Pharmacology (San Diego, Calif.). 64: 1-25. PMID 22840743 DOI: 10.1016/B978-0-12-394816-8.00001-5 |
0.302 |
|
| 2012 |
Kusuma BR, Zhang L, Sundstrom T, Peterson LB, Dobrowsky RT, Blagg BS. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity. Journal of Medicinal Chemistry. 55: 5797-812. PMID 22702513 DOI: 10.1021/Jm300544C |
0.641 |
|
| 2012 |
Duerfeldt AS, Peterson LB, Maynard JC, Ng CL, Eletto D, Ostrovsky O, Shinogle HE, Moore DS, Argon Y, Nicchitta CV, Blagg BS. Development of a Grp94 inhibitor. Journal of the American Chemical Society. 134: 9796-804. PMID 22642269 DOI: 10.1021/Ja303477G |
0.837 |
|
| 2012 |
Peterson LB, Eskew JD, Vielhauer GA, Blagg BS. The hERG channel is dependent upon the Hsp90α isoform for maturation and trafficking. Molecular Pharmaceutics. 9: 1841-6. PMID 22554505 DOI: 10.1021/Mp300138N |
0.685 |
|
| 2012 |
Woodruff D, Sadikot T, Eskew J, Blagg B, Vielhauer G, Holzbeierlein J. 486 Development Of A High-Throughput Screening Assay For The Identification Of Cancer Cell-Specific Hsp90 The Journal of Urology. 187. DOI: 10.1016/J.Juro.2012.02.555 |
0.359 |
|
| 2011 |
Brandt GE, Blagg BS. Monoenomycin: A Simplified Trienomycin A Analogue that Manifests Anticancer Activity. Acs Medicinal Chemistry Letters. 2: 735-740. PMID 22162786 DOI: 10.1021/ml200108y |
0.793 |
|
| 2011 |
Eskew JD, Sadikot T, Morales P, Duren A, Dunwiddie I, Swink M, Zhang X, Hembruff S, Donnelly A, Rajewski RA, Blagg BS, Manjarrez JR, Matts RL, Holzbeierlein JM, Vielhauer GA. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. Bmc Cancer. 11: 468. PMID 22039910 DOI: 10.1186/1471-2407-11-468 |
0.761 |
|
| 2011 |
Kusuma BR, Duerfeldt AS, Blagg BS. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters. 21: 7170-4. PMID 22014546 DOI: 10.1016/J.Bmcl.2011.09.073 |
0.825 |
|
| 2011 |
Samadi AK, Zhang X, Mukerji R, Donnelly AC, Blagg BS, Cohen MS. A novel C-terminal HSP90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells. Cancer Letters. 312: 158-67. PMID 21924824 DOI: 10.1016/J.Canlet.2011.07.031 |
0.741 |
|
| 2011 |
Kusuma BR, Peterson LB, Zhao H, Vielhauer G, Holzbeierlein J, Blagg BS. Targeting the heat shock protein 90 dimer with dimeric inhibitors. Journal of Medicinal Chemistry. 54: 6234-53. PMID 21861487 DOI: 10.1021/Jm200553W |
0.644 |
|
| 2011 |
Zhao H, Donnelly AC, Kusuma BR, Brandt GE, Brown D, Rajewski RA, Vielhauer G, Holzbeierlein J, Cohen MS, Blagg BS. Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents. Journal of Medicinal Chemistry. 54: 3839-53. PMID 21553822 DOI: 10.1021/Jm200148P |
0.814 |
|
| 2011 |
Matts RL, Dixit A, Peterson LB, Sun L, Voruganti S, Kalyanaraman P, Hartson SD, Verkhivker GM, Blagg BS. Elucidation of the Hsp90 C-terminal inhibitor binding site. Acs Chemical Biology. 6: 800-7. PMID 21548602 DOI: 10.1021/Cb200052X |
0.616 |
|
| 2011 |
Davenport J, Manjarrez JR, Peterson L, Krumm B, Blagg BS, Matts RL. Gambogic acid, a natural product inhibitor of Hsp90. Journal of Natural Products. 74: 1085-92. PMID 21486005 DOI: 10.1021/Np200029Q |
0.696 |
|
| 2011 |
Zhao H, Brandt GE, Galam L, Matts RL, Blagg BS. Identification and initial SAR of silybin: an Hsp90 inhibitor. Bioorganic & Medicinal Chemistry Letters. 21: 2659-64. PMID 21273068 DOI: 10.1016/J.Bmcl.2010.12.088 |
0.837 |
|
| 2011 |
Matts RL, Brandt GE, Lu Y, Dixit A, Mollapour M, Wang S, Donnelly AC, Neckers L, Verkhivker G, Blagg BS. A systematic protocol for the characterization of Hsp90 modulators. Bioorganic & Medicinal Chemistry. 19: 684-92. PMID 21129982 DOI: 10.1016/J.Bmc.2010.10.029 |
0.8 |
|
| 2011 |
James A, Holzbeierlein J, Eskew J, Blagg B, Rajewski R, Vielhauer G. 610 In Vivo Efficacy Of Ku-174, A C-Terminal Inhibitor Of Hsp90 In A Pc3 Xenograft Model The Journal of Urology. 185. DOI: 10.1016/J.Juro.2011.02.1463 |
0.424 |
|
| 2011 |
Samadi A, Mukerji R, Zhang X, Blagg B, Cohen M. KU135 a HPS90 Inhibitor Induced Cell Death In Melanoma Cells Journal of Surgical Research. 165: 177. DOI: 10.1016/J.Jss.2010.11.760 |
0.318 |
|
| 2010 |
Zhao H, Kusuma BR, Blagg BS. Synthesis and Evaluation of Noviose Replacements on Novobiocin that Manifest Anti-proliferative Activity. Acs Medicinal Chemistry Letters. 1: 311-315. PMID 21904660 DOI: 10.1021/Ml100070R |
0.406 |
|
| 2010 |
Duerfeldt AS, Blagg BS. Hsp90 inhibition: elimination of shock and stress. Bioorganic & Medicinal Chemistry Letters. 20: 4983-7. PMID 20656483 DOI: 10.1016/J.Bmcl.2010.06.108 |
0.837 |
|
| 2010 |
Peterson LB, Blagg BS. Click chemistry to probe Hsp90: Synthesis and evaluation of a series of triazole-containing novobiocin analogues. Bioorganic & Medicinal Chemistry Letters. 20: 3957-60. PMID 20570149 DOI: 10.1016/J.Bmcl.2010.04.140 |
0.687 |
|
| 2010 |
Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, Lee S, Morra G, Bourboulia D, Scroggins BT, Colombo G, Blagg BS, Panaretou B, Stetler-Stevenson WG, Trepel JB, et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Molecular Cell. 37: 333-43. PMID 20159553 DOI: 10.1016/J.Molcel.2010.01.005 |
0.769 |
|
| 2010 |
Mays JR, Hill SA, Moyers JT, Blagg BS. The synthesis and evaluation of flavone and isoflavone chimeras of novobiocin and derrubone. Bioorganic & Medicinal Chemistry. 18: 249-66. PMID 19932969 DOI: 10.1016/j.bmc.2009.10.061 |
0.378 |
|
| 2010 |
Matthews SB, Vielhauer GA, Manthe CA, Chaguturu VK, Szabla K, Matts RL, Donnelly AC, Blagg BS, Holzbeierlein JM. Characterization of a novel novobiocin analogue as a putative C-terminal inhibitor of heat shock protein 90 in prostate cancer cells. The Prostate. 70: 27-36. PMID 19739131 DOI: 10.1002/Pros.21035 |
0.745 |
|
| 2010 |
Donnelly AC, Zhao H, Reddy Kusuma B, Blagg BSJ. Cytotoxic sugar analogues of an optimized novobiocin scaffold Medchemcomm. 1: 165-170. DOI: 10.1039/C0Md00063A |
0.74 |
|
| 2010 |
Waldron RT, Peterson LB, Blagg B, Rozengurt E. M1705 Curcumin and Curcumin Analogues Inhibit Mitogenic Signaling in Normal Intestinal Epithelial Cells Gastroenterology. 138: S-402. DOI: 10.1016/S0016-5085(10)61848-3 |
0.581 |
|
| 2009 |
Peterson LB, Blagg BS. To fold or not to fold: modulation and consequences of Hsp90 inhibition. Future Medicinal Chemistry. 1: 267-83. PMID 20161407 DOI: 10.4155/Fmc.09.17 |
0.657 |
|
| 2009 |
Jadhav VD, Duerfeldt AS, Blagg BS. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 6845-50. PMID 19896848 DOI: 10.1016/J.Bmcl.2009.10.091 |
0.838 |
|
| 2009 |
Brandt GE, Blagg BS. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases. Current Topics in Medicinal Chemistry. 9: 1447-61. PMID 19860731 DOI: 10.2174/156802609789895683 |
0.839 |
|
| 2009 |
Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, Szabla K, Tanol M, Vielhauer GA, Rajewski RA, Matts RL, Blagg BS, Robertson JD. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Molecular Pharmacology. 76: 1314-22. PMID 19741006 DOI: 10.1124/Mol.109.058545 |
0.784 |
|
| 2009 |
Hadden MK, Blagg BS. Synthesis and evaluation of radamide analogues, a chimera of radicicol and geldanamycin. The Journal of Organic Chemistry. 74: 4697-704. PMID 19492825 DOI: 10.1021/jo900278g |
0.743 |
|
| 2009 |
Duerfeldt AS, Brandt GE, Blagg BS. Design, synthesis, and biological evaluation of conformationally constrained cis-amide Hsp90 inhibitors. Organic Letters. 11: 2353-6. PMID 19435295 DOI: 10.1021/Ol900783M |
0.825 |
|
| 2009 |
Duerfeldt AS, Blagg BS. Hydrating for resistance to radicicol. Acs Chemical Biology. 4: 245-7. PMID 19371133 DOI: 10.1021/Cb9000712 |
0.809 |
|
| 2009 |
Immormino RM, Metzger LE, Reardon PN, Dollins DE, Blagg BS, Gewirth DT. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. Journal of Molecular Biology. 388: 1033-42. PMID 19361515 DOI: 10.1016/J.Jmb.2009.03.071 |
0.407 |
|
| 2009 |
Amolins MW, Blagg BS. Natural product inhibitors of Hsp90: potential leads for drug discovery. Mini Reviews in Medicinal Chemistry. 9: 140-52. PMID 19200020 DOI: 10.2174/138955709787316056 |
0.328 |
|
| 2009 |
Hadden MK, Hill SA, Davenport J, Matts RL, Blagg BS. Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorganic & Medicinal Chemistry. 17: 634-40. PMID 19101151 DOI: 10.1016/J.Bmc.2008.11.064 |
0.744 |
|
| 2009 |
Amolins MW, Peterson LB, Blagg BS. Synthesis and evaluation of electron-rich curcumin analogues. Bioorganic & Medicinal Chemistry. 17: 360-7. PMID 19019687 DOI: 10.1016/J.Bmc.2008.10.057 |
0.592 |
|
| 2008 |
Wang M, Blagg BS. Synthesis of a versatile metacyclophane macrolactam. Tetrahedron Letters. 49: 141-144. PMID 19568319 DOI: 10.1016/j.tetlet.2007.10.150 |
0.386 |
|
| 2008 |
Donnelly A, Blagg BS. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Current Medicinal Chemistry. 15: 2702-17. PMID 18991631 DOI: 10.2174/092986708786242895 |
0.784 |
|
| 2008 |
Donnelly AC, Mays JR, Burlison JA, Nelson JT, Vielhauer G, Holzbeierlein J, Blagg BS. The design, synthesis, and evaluation of coumarin ring derivatives of the novobiocin scaffold that exhibit antiproliferative activity. The Journal of Organic Chemistry. 73: 8901-20. PMID 18939877 DOI: 10.1021/Jo801312R |
0.829 |
|
| 2008 |
Hadden MK, Blagg BS. Dimeric approaches to anti-cancer chemotherapeutics. Anti-Cancer Agents in Medicinal Chemistry. 8: 807-16. PMID 18855582 |
0.658 |
|
| 2008 |
Brandt GE, Schmidt MD, Prisinzano TE, Blagg BS. Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. Journal of Medicinal Chemistry. 51: 6495-502. PMID 18816111 DOI: 10.1021/Jm8007486 |
0.85 |
|
| 2008 |
Burlison JA, Avila C, Vielhauer G, Lubbers DJ, Holzbeierlein J, Blagg BS. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines. The Journal of Organic Chemistry. 73: 2130-7. PMID 18293999 DOI: 10.1021/Jo702191A |
0.806 |
|
| 2008 |
Tash JS, Chakrasali R, Jakkaraj SR, Hughes J, Smith SK, Hornbaker K, Heckert LL, Ozturk SB, Hadden MK, Kinzy TG, Blagg BS, Georg GI. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets HSP90AB1 (HSP90BETA) and EEF1A1 (eEF1A), and stimulates Il1a transcription in rat Sertoli cells. Biology of Reproduction. 78: 1139-52. PMID 18218611 DOI: 10.1095/Biolreprod.107.062679 |
0.713 |
|
| 2008 |
Hastings JM, Hadden MK, Blagg BS. Synthesis and evaluation of derrubone and select analogues. The Journal of Organic Chemistry. 73: 369-73. PMID 18154304 DOI: 10.1021/jo702366g |
0.694 |
|
| 2008 |
Hirsch B, Rohr M, Patton B, Blagg B, Herre WR, Cohen MS. 52. A Novel Small Molecule HSP90 Inhibitor With Antiproliferative Effects in Differentiated and Anaplastic Thyroid Cancers Journal of Surgical Research. 144: 198. DOI: 10.1016/J.Jss.2007.12.060 |
0.411 |
|
| 2008 |
Michaelis ML, Ansar S, Chigurupati R, Menchen H, Blagg B, Rajewski R. P2-384: In vivo
effects of novel Hsp90 C-terminal inhibitors in Tau mutant mice Alzheimer's & Dementia. 4: T485-T485. DOI: 10.1016/J.Jalz.2008.05.1462 |
0.372 |
|
| 2007 |
Hadden MK, Galam L, Gestwicki JE, Matts RL, Blagg BS. Derrubone, an inhibitor of the Hsp90 protein folding machinery. Journal of Natural Products. 70: 2014-8. PMID 18020309 DOI: 10.1021/Np070190S |
0.737 |
|
| 2007 |
Bishop SC, Burlison JA, Blagg BS. Hsp90: a novel target for the disruption of multiple signaling cascades. Current Cancer Drug Targets. 7: 369-88. PMID 17979631 DOI: 10.2174/156800907780809778 |
0.804 |
|
| 2007 |
Hadden MK, Blagg BS. Cytotoxic small molecule dimers and their inhibitory activity against human breast cancer cells. Bioorganic & Medicinal Chemistry Letters. 17: 5063-7. PMID 17656092 DOI: 10.1016/j.bmcl.2007.07.014 |
0.652 |
|
| 2007 |
Huang YT, Blagg BS. A library of noviosylated coumarin analogues. The Journal of Organic Chemistry. 72: 3609-13. PMID 17328573 DOI: 10.1021/jo062083t |
0.42 |
|
| 2007 |
Ansar S, Burlison JA, Hadden MK, Yu XM, Desino KE, Bean J, Neckers L, Audus KL, Michaelis ML, Blagg BS. A non-toxic Hsp90 inhibitor protects neurons from Abeta-induced toxicity. Bioorganic & Medicinal Chemistry Letters. 17: 1984-90. PMID 17276679 DOI: 10.1016/J.Bmcl.2007.01.017 |
0.807 |
|
| 2007 |
Galam L, Hadden MK, Ma Z, Ye QZ, Yun BG, Blagg BS, Matts RL. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. Bioorganic & Medicinal Chemistry. 15: 1939-46. PMID 17223347 DOI: 10.1016/J.Bmc.2007.01.004 |
0.717 |
|
| 2006 |
Duvvuri M, Konkar S, Hong KH, Blagg BS, Krise JP. A new approach for enhancing differential selectivity of drugs to cancer cells. Acs Chemical Biology. 1: 309-15. PMID 17163760 DOI: 10.1021/Cb6001202 |
0.328 |
|
| 2006 |
Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. Journal of the American Chemical Society. 128: 15529-36. PMID 17132020 DOI: 10.1021/Ja065793P |
0.814 |
|
| 2006 |
Burlison JA, Blagg BS. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery. Organic Letters. 8: 4855-8. PMID 17020320 DOI: 10.1021/Ol061918J |
0.833 |
|
| 2006 |
Shen G, Wang M, Welch TR, Blagg BS. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90. The Journal of Organic Chemistry. 71: 7618-31. PMID 16995666 DOI: 10.1021/Jo061054F |
0.637 |
|
| 2006 |
Elliott GI, Fuchs JR, Blagg BS, Ishikawa H, Tao H, Yuan ZQ, Boger DL. Intramolecular diels-alder/1,3-dipolar cycloaddition cascade of 1,3,4-oxadiazoles. Journal of the American Chemical Society. 128: 10589-95. PMID 16895427 DOI: 10.1021/Ja0612549 |
0.647 |
|
| 2006 |
Hadden MK, Lubbers DJ, Blagg BS. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 N-terminal ATP binding site. Current Topics in Medicinal Chemistry. 6: 1173-82. PMID 16842154 DOI: 10.2174/156802606777812031 |
0.739 |
|
| 2006 |
Avila C, Hadden MK, Ma Z, Kornilayev BA, Ye QZ, Blagg BS. High-throughput screening for Hsp90 ATPase inhibitors. Bioorganic & Medicinal Chemistry Letters. 16: 3005-8. PMID 16530412 DOI: 10.1016/j.bmcl.2006.02.063 |
0.654 |
|
| 2006 |
Wang M, Shen G, Blagg BS. Radanamycin, a macrocyclic chimera of radicicol and geldanamycin. Bioorganic & Medicinal Chemistry Letters. 16: 2459-62. PMID 16464590 DOI: 10.1016/J.Bmcl.2006.01.086 |
0.617 |
|
| 2006 |
Blagg BS, Kerr TD. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation. Medicinal Research Reviews. 26: 310-38. PMID 16385472 DOI: 10.1002/med.20052 |
0.415 |
|
| 2006 |
Avila C, Kornilayev BA, Blagg BS. Development and optimization of a useful assay for determining Hsp90's inherent ATPase activity. Bioorganic & Medicinal Chemistry. 14: 1134-42. PMID 16213144 DOI: 10.1016/j.bmc.2005.09.027 |
0.399 |
|
| 2005 |
Yu XM, Shen G, Neckers L, Blake H, Holzbeierlein J, Cronk B, Blagg BS. Hsp90 inhibitors identified from a library of novobiocin analogues. Journal of the American Chemical Society. 127: 12778-9. PMID 16159253 DOI: 10.1021/Ja0535864 |
0.614 |
|
| 2005 |
Shen G, Blagg BS. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Organic Letters. 7: 2157-60. PMID 15901158 DOI: 10.1021/Ol050580A |
0.61 |
|
| 2004 |
Clevenger RC, Blagg BS. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Organic Letters. 6: 4459-62. PMID 15548050 DOI: 10.1021/Ol048266O |
0.432 |
|
| 2004 |
Shen G, Yu XM, Blagg BS. Syntheses of photolabile novobiocin analogues. Bioorganic & Medicinal Chemistry Letters. 14: 5903-6. PMID 15501066 DOI: 10.1016/J.Bmcl.2004.09.017 |
0.502 |
|
| 2004 |
Yu XM, Shen G, Blagg BS. Synthesis of (-)-noviose from 2,3-O-isopropylidene-D-erythronolactol. The Journal of Organic Chemistry. 69: 7375-8. PMID 15471498 DOI: 10.1021/Jo048953T |
0.422 |
|
| 2004 |
Clevenger RC, Raibel JM, Peck AM, Blagg BS. Biotinylated geldanamycin. The Journal of Organic Chemistry. 69: 4375-80. PMID 15202892 DOI: 10.1021/jo049848m |
0.434 |
|
| 2002 |
Wilkie GD, Elliott GI, Blagg BS, Wolkenberg SE, Soenen DR, Miller MM, Pollack S, Boger DL. Intramolecular Diels-Alder and tandem intramolecular Diels-Alder/1,3-dipolar cycloaddition reactions of 1,3,4-oxadiazoles. Journal of the American Chemical Society. 124: 11292-4. PMID 12236743 DOI: 10.1021/Ja027533N |
0.733 |
|
| 2002 |
Blagg BS, Jarstfer MB, Rogers DH, Poulter CD. Recombinant squalene synthase. A mechanism for the rearrangement of presqualene diphosphate to squalene. Journal of the American Chemical Society. 124: 8846-53. PMID 12137537 DOI: 10.1021/Ja020411A |
0.489 |
|
| 2002 |
Koppisch AT, Fox DT, Blagg BS, Poulter CD. E. coli MEP synthase: steady-state kinetic analysis and substrate binding. Biochemistry. 41: 236-43. PMID 11772021 DOI: 10.1021/Bi0118207 |
0.735 |
|
| 2002 |
Blagg BSJ, Boger DL. Total synthesis of (+)-camptothecin Tetrahedron. 58: 6343-6349. DOI: 10.1016/S0040-4020(02)00633-6 |
0.506 |
|
| 2001 |
Hahn FM, Eubanks LM, Testa CA, Blagg BS, Baker JA, Poulter CD. 1-Deoxy-D-xylulose 5-phosphate synthase, the gene product of open reading frame (ORF) 2816 and ORF 2895 in Rhodobacter capsulatus. Journal of Bacteriology. 183: 1-11. PMID 11114895 DOI: 10.1128/Jb.183.1.1-11.2001 |
0.743 |
|
| 2000 |
Koppisch AT, Blagg BS, Poulter CD. Synthesis of 2-C-methyl-D-erythritol 4-phosphate: the first pathway-specific intermediate in the methylerythritol phosphate route to isoprenoids. Organic Letters. 2: 215-7. PMID 10814285 DOI: 10.1021/Ol991299X |
0.735 |
|
| 1999 |
Blagg BS, Poulter CD. Synthesis of 1-Deoxy-D-xylulose and 1-Deoxy-D-xylulose-5-phosphate. The Journal of Organic Chemistry. 64: 1508-1511. PMID 11674212 DOI: 10.1021/Jo981966K |
0.44 |
|
| 1996 |
Jarstfer MB, Blagg BSJ, Rogers DH, Poulter CD. Biosynthesis of squalene. Evidence for a tertiary cyclopropylcarbinyl cationic intermediate in the rearrangement of presqualene disphosphate to squalene Journal of the American Chemical Society. 118: 13089-13090. DOI: 10.1021/Ja963308S |
0.406 |
|
| Show low-probability matches. |